Mayne Pharma Group
- Short interest
- 2.27%
- +0.02 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 1.9M
- Shares on issue
- 81.891M
Mayne Pharma Group (MYX) Short Interest
Mayne Pharma Group (ASX:MYX) had 2.27% of shares reported as short positions as of 8 Oct 2026, representing 1,858,075 shares. Mayne Pharma Group operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Mayne Pharma Group
Mayne Pharma Group Limited is a specialty pharmaceutical company listed on the ASX, focused on commercializing pharmaceuticals and improving patient access to life-enhancing medications. The company has a 40-year track record of innovation in developing oral drug delivery systems, offering a portfolio of branded and generic drugs in therapeutic areas like women's health and dermatology.
Company profile →Mayne Pharma Group (ASX:MYX) has 2.27% of its shares on issue reported as short positions as of 8 Oct 2026, or about 1,858,075 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.22 percentage points. Its highest recorded short interest was 13.53% in May 2017. MYX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads MYX today
- Zanger BreakoutWatchScore 6rank 1886 of 1942
- CAN SLIMWatchScore 21rank 620 of 1541
- Minervini Trend TemplateWatchScore 24rank 707 of 1716
- Crowded-Short BreakoutWatchScore 19rank 366 of 1502
- Quality compoundersWatchScore 21rank 714 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
MYX fundamentals
In the year to 30 Jun 2026, Mayne Pharma Group (ASX:MYX) recorded revenue of A$378.4M and net profit after tax of A$24.5M. Net margin 6.5% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest MYX news
All news- Supreme Court Decision in Cosette Proceedings
asx · 13 Oct 2026
- Trading Halt
asx · 13 Oct 2026
- Fulfilment of Imvexxy post-marketing study requirements
asx · 8 Oct 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss MYX
Start a research thread or post the first pulse update